You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 111 No. 1, January 1993 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  LABORATORY SCIENCES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (25)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Pharmacokinetics of Newer Cephalosporins After Subconjunctival and Intravitreal Injection in Rabbits

Michael Barza, MD; Elizabeth Lynch, MS; Jules L. Baum, MD

Arch Ophthalmol. 1993;111(1):121-125.


Abstract



• Pharmacologic considerations suggest that third-generation cephalosporins might penetrate the vitreous humor better after periocular injection and might be eliminated less readily after intravitreous injection than older agents. We studied the sodium salts of ceftizoxime, ceftriaxone, and ceftazidime, and of an investigational cephalosporin, cefepime, in rabbits. After a single subconjunctival injection in animals with normal eyes, vitreous levels ranged from 3 to 13 mg/L. After five subconjunctival injections in rabbits with infected eyes, vitreous concentrations ranged from 12 to 34 mg/L. These concentrations are not appreciably greater than those found with older β-lactams. The vitreous half-life of the four drugs after intravitreous injection varied from 5.7 to 20 hours in rabbits with uninflamed eyes and from 9.4 to 21.5 hours in rabbits with infected eyes. Except for ceftizoxime, the half-lives were substantially longer than those for older β-lactams and suggest predominantly anterior route elimination. Vitreous penetration of these new agents after subconjunctival injection does not appear to be sufficient to overcome the need for intravitreous injections in the treatment of endophthalmitis. However, the longer vitreous half-lives of some of the newer agents may be useful if the drugs are to be given intravitreally.



Author Affiliations



From the Department of Medicine, Division of Geographic Medicine and Infectious Disease, New England Medical Center, Boston, Mass (Dr Barza and Ms Lynch), and Tufts University School of Medicine (Dr Baum), Boston. The authors have no commercial or proprietary interest in the products named or the manufacturing companies listed. Dr Barza has received honoraria for lectures from Roche Laboratories, Nutley, NJ, and Glaxo, Research Triangle Park, NC.


Footnotes



Accepted for publication September 10, 1992.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacokinetics of Sparfloxacin in the Serum and Vitreous Humor of Rabbits: Physicochemical Properties That Regulate Penetration of Quinolone Antimicrobials
Liu et al.
Antimicrob. Agents Chemother. 1998;42:1417-1423.
ABSTRACT | FULL TEXT  

Comparative Intravitreal Antibiotic Therapy for Experimental Enterococcus faecalis Endophthalmitis
Choi et al.
Arch Ophthalmol 1996;114:61-65.
ABSTRACT  

Ocular Penetration of Ceftriaxone, Ceftazidime, and Vancomycin After Subconjunctival Injection in Humans
Barza et al.
Arch Ophthalmol 1993;111:492-494.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.